
Molecular Docking and Design of Novel Heterodimers of Donepezil and Huperzine Fragments as Acetylcholinesterase Inhibitors
English
Molecular Docking and Design of Novel Heterodimers of Donepezil and Huperzine Fragments as Acetylcholinesterase Inhibitors
-
Key words:
- molecular docking
- / acetylcholinesterase
- / Alzheimer's disease
-
-
-
[1]
(1) An, P.; Singh, B.; Singh, N. A review on coumarins as acetylcholinesterase inhibitors for zheimer's disease. Bioorganic & Medicinal Chemistry 2012, 20, 1175–1180.(1) An, P.; Singh, B.; Singh, N. A review on coumarins as acetylcholinesterase inhibitors for zheimer's disease. Bioorganic & Medicinal Chemistry 2012, 20, 1175–1180.
-
[2]
(2) Hu, Y. Q.; Zhang, J.; Chandrashankra, O.; Ip, F. C. F.; Ip, N. Y. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 2013, 21, 676–683.(2) Hu, Y. Q.; Zhang, J.; Chandrashankra, O.; Ip, F. C. F.; Ip, N. Y. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 2013, 21, 676–683.
-
[3]
(3) Shen, L. L.; Liu, G. X.; Tang, Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol Sin. 2007, 28, 2053–2063.(3) Shen, L. L.; Liu, G. X.; Tang, Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol Sin. 2007, 28, 2053–2063.
-
[4]
(4) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew. Chem., Int. Ed. 2000, 39, 1775–1777.(4) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew. Chem., Int. Ed. 2000, 39, 1775–1777.
-
[5]
(5) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335–2338.(5) Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335–2338.
-
[6]
(6) Alonso, D.; Dorronsoro, I.; Rubio, L.; Muñz, P.; García-Palomero, E.; Del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Castro, A.; Medina, M.; Martínez, A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem. 2005, 13, 6588–6597.(6) Alonso, D.; Dorronsoro, I.; Rubio, L.; Muñz, P.; García-Palomero, E.; Del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Castro, A.; Medina, M.; Martínez, A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem. 2005, 13, 6588–6597.
-
[7]
(7) Shao, D.; Zou, C.; Luo, C.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Bioorg. Med. Chem. Lett. 2004, 14, 4639–4642.(7) Shao, D.; Zou, C.; Luo, C.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Bioorg. Med. Chem. Lett. 2004, 14, 4639–4642.
-
[8]
(8) Camps, P.; Formosa, X.; Galdeano, C.; Gomez, T.; Munoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M. V.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J. J. Med. Chem. 2008, 51, 3588–3598.(8) Camps, P.; Formosa, X.; Galdeano, C.; Gomez, T.; Munoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M. V.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J. J. Med. Chem. 2008, 51, 3588–3598.
-
[9]
(9) Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem. 2010, 17, 1825–1838.(9) Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem. 2010, 17, 1825–1838.
-
[10]
(10) Viayna, E.; Gomez, T.; Galdeano, C.; Ramirez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Munoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-alzheimer drug candidates. Chem. Med. Chem. 2010, 5, 1855–1870.(10) Viayna, E.; Gomez, T.; Galdeano, C.; Ramirez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Munoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-alzheimer drug candidates. Chem. Med. Chem. 2010, 5, 1855–1870.
-
[11]
(11) Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J. Mol. Neurosci. 2006, 30, 85–88.(11) Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J. Mol. Neurosci. 2006, 30, 85–88.
-
[12]
(12) Chitranshi, N.; Gupta, S.; Tripathi, P. K.; Seth, P. K. New molecular scaffolds for the design of Alzheimer's acetylcholinesterase inhibitors identified using ligand and receptor-based virtual screening. Med. Chem. Res. 2013, 22, 2328–2345.(12) Chitranshi, N.; Gupta, S.; Tripathi, P. K.; Seth, P. K. New molecular scaffolds for the design of Alzheimer's acetylcholinesterase inhibitors identified using ligand and receptor-based virtual screening. Med. Chem. Res. 2013, 22, 2328–2345.
-
[13]
(13) Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078–1082.(13) Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078–1082.
-
[14]
(14) Drews, J. Drug discovery: a historical perspective. Science 2000, 287, 1960–1964.(14) Drews, J. Drug discovery: a historical perspective. Science 2000, 287, 1960–1964.
-
[15]
(15) Deb, P. K.; Sharma, A.; Piplani, P.; Akkinepally, R. R. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Mol. Divers. 2012, 16, 803–823.(15) Deb, P. K.; Sharma, A.; Piplani, P.; Akkinepally, R. R. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Mol. Divers. 2012, 16, 803–823.
-
[16]
(16) Steiner, S.; Anderson, N. L. Pharmaceutical proteomics. AnnNY Acad Sci. 2000, 919, 48–51.(16) Steiner, S.; Anderson, N. L. Pharmaceutical proteomics. AnnNY Acad Sci. 2000, 919, 48–51.
-
[17]
(17) Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; Haystead, T. A. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 2002, 62, 1364–1372.(17) Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; Haystead, T. A. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 2002, 62, 1364–1372.
-
[18]
(18) Bruneau, J. M.; Maillet, J.; Tagat, E. Drug induced proteome changes in Candida albicans: comparison of the effect of beta (1, 3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 2003, 3, 325–336.(18) Bruneau, J. M.; Maillet, J.; Tagat, E. Drug induced proteome changes in Candida albicans: comparison of the effect of beta (1, 3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 2003, 3, 325–336.
-
[19]
(19) Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterasein complex with pharmacologically important ligands. J. Med. Chem. 2012, 55, 10282–10286.(19) Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterasein complex with pharmacologically important ligands. J. Med. Chem. 2012, 55, 10282–10286.
-
[20]
(20) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Mont Gomery, Jr. J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision C. 02, Gaussian, Inc., Wallingford CT 2004.(20) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Mont Gomery, Jr. J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision C. 02, Gaussian, Inc., Wallingford CT 2004.
-
[21]
(21) Kryger, G.; Silman, I.; Sussman, J. L. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J. Physiol. Paris 1998, 92, 191–194.(21) Kryger, G.; Silman, I.; Sussman, J. L. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J. Physiol. Paris 1998, 92, 191–194.
-
[22]
(22) Nachon, F.; Carletti, E.; Ronco, C.; Trovaslet, M.; Nicolet, Y.; Jean, L.; Renard, P. Y. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl-and butyryl-cholinesterase. Biochem. J. 2013, 453, 393–399.(22) Nachon, F.; Carletti, E.; Ronco, C.; Trovaslet, M.; Nicolet, Y.; Jean, L.; Renard, P. Y. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl-and butyryl-cholinesterase. Biochem. J. 2013, 453, 393–399.
-
[23]
(23) Carletti, E.; Colletier, J. P.; Dupeux, F.; Trovaslet, M.; Masson, P.; Nachon, F. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. J. Med. Chem. 2010, 53, 4002–4008.(23) Carletti, E.; Colletier, J. P.; Dupeux, F.; Trovaslet, M.; Masson, P.; Nachon, F. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. J. Med. Chem. 2010, 53, 4002–4008.
-
[24]
(24) Taylor, J. L.; Mayer, R. H.; Hime, C. M. Conformers of acetylcholinesterase: a mechanism of allosteric control. Mol. Pharmacol. 1994, 45, 74–83.(24) Taylor, J. L.; Mayer, R. H.; Hime, C. M. Conformers of acetylcholinesterase: a mechanism of allosteric control. Mol. Pharmacol. 1994, 45, 74–83.
-
[25]
(25) Pang, Y. P.; Quiram, P.; Jalacie, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646–23649.(25) Pang, Y. P.; Quiram, P.; Jalacie, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646–23649.
-
[26]
(26) Bolognes, M. L.; Banzi, R.; Bartolini, M.; Cavall, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem. 2007, 50, 4882–4897.(26) Bolognes, M. L.; Banzi, R.; Bartolini, M.; Cavall, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem. 2007, 50, 4882–4897.
-
[27]
(27) Bolognesi, M. L.; Bartolini, M.; Mancin, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. Chem. Med. Chem. 2010, 5, 1215–1220.(27) Bolognesi, M. L.; Bartolini, M.; Mancin, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. Chem. Med. Chem. 2010, 5, 1215–1220.
-
[28]
(28) Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297–307.(28) Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297–307.
-
[29]
(29) Volkov, A.; King, H. F.; Coppens, P.; Farrugia, L. On the calculation of the electrostatic potential, electric field and electric field gradient from the aspherical pseudoatom model. Acta Crystallogr. A 2006, 62, 400–408.(29) Volkov, A.; King, H. F.; Coppens, P.; Farrugia, L. On the calculation of the electrostatic potential, electric field and electric field gradient from the aspherical pseudoatom model. Acta Crystallogr. A 2006, 62, 400–408.
-
[30]
(30) Luger, P.; Hübschle, C. B. MolIso–a program for colour-mapped iso-surfaces. J. Appl. Crystallogr. 2006, 39, 901–904.(30) Luger, P.; Hübschle, C. B. MolIso–a program for colour-mapped iso-surfaces. J. Appl. Crystallogr. 2006, 39, 901–904.
-
[31]
(31) Luger, P.; Weber, M.; Dittrich, B. Electron density study of the anti-Alzheimer's disease drug donepezil from conventionalx-ray data and invariom database application. Future Med. Chem. 2012, 4, 1399–1407.(31) Luger, P.; Weber, M.; Dittrich, B. Electron density study of the anti-Alzheimer's disease drug donepezil from conventionalx-ray data and invariom database application. Future Med. Chem. 2012, 4, 1399–1407.
-
[32]
(32) Chen, J. W.; Luo, Y. L.; Hwang, M. J.; Peng, F. C.; Ling, K. H. A tremorgenic mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding mechanism. J. Biol. Chem. 1999, 274, 34916–34923.(32) Chen, J. W.; Luo, Y. L.; Hwang, M. J.; Peng, F. C.; Ling, K. H. A tremorgenic mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding mechanism. J. Biol. Chem. 1999, 274, 34916–34923.
-
[33]
(33) Ling, K. H.; Chiou, C. M.; Tseng, Y. L. Biotransformation of territrems by S9 fraction from rat liver. Drug Metab. Dispos. 1991, 19, 587–595.(33) Ling, K. H.; Chiou, C. M.; Tseng, Y. L. Biotransformation of territrems by S9 fraction from rat liver. Drug Metab. Dispos. 1991, 19, 587–595.
-
[34]
(34) Wu, W. J.; Lai, R.; Zheng, K. C.; Yun, F. C. Quantitative structure-activity relationship of indolo[1,2-b] quinazoline derivatives with antitumor activity. Acta Phys.-Chim. Sin. 2005, 21, 28–32.(34) Wu, W. J.; Lai, R.; Zheng, K. C.; Yun, F. C. Quantitative structure-activity relationship of indolo[1,2-b] quinazoline derivatives with antitumor activity. Acta Phys.-Chim. Sin. 2005, 21, 28–32.
-
[35]
(35) Wang, X. W.; Jiang, G.; Du, J. G. Structures, infrared spectra and reactivities of (+)-catechin metal complexes. Acta Phys. Chim. Sin. 2011, 27, 309–314.(35) Wang, X. W.; Jiang, G.; Du, J. G. Structures, infrared spectra and reactivities of (+)-catechin metal complexes. Acta Phys. Chim. Sin. 2011, 27, 309–314.
-
[36]
(36) Feng, C. J. Theoretical studies on quantitative structure-activity relationship and structural modification for 3-substituted sulfur-5-(2-hydroxyphenyl)-4H-1,2,4-triazole compounds. Acta Chimica Sinica 2012, 4, 512–518.(36) Feng, C. J. Theoretical studies on quantitative structure-activity relationship and structural modification for 3-substituted sulfur-5-(2-hydroxyphenyl)-4H-1,2,4-triazole compounds. Acta Chimica Sinica 2012, 4, 512–518.
-
[37]
(37) Zhang, J.; Shen, P.; Lu, T.; Yu, D. N.; Li, H.; Yang, G. Z. Theoretical studies on quantitative structure-activity relationship and structural modification for the inhibition of MMP-9 by flavonoids. Acta Chimica Sinica 2011, 4, 383–392.(37) Zhang, J.; Shen, P.; Lu, T.; Yu, D. N.; Li, H.; Yang, G. Z. Theoretical studies on quantitative structure-activity relationship and structural modification for the inhibition of MMP-9 by flavonoids. Acta Chimica Sinica 2011, 4, 383–392.
-
[38]
(38) Aihara, J. I. Weighted HOMO LUMO energy separation as an index of kinetic stability for fullerenes. Theor. Chem. Acc. 1999, 102, 134-138.(38) Aihara, J. I. Weighted HOMO LUMO energy separation as an index of kinetic stability for fullerenes. Theor. Chem. Acc. 1999, 102, 134-138.
-
[39]
(39) Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics. Modell. 2002, 20, 281–295.(39) Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics. Modell. 2002, 20, 281–295.
-
[1]
-

计量
- PDF下载量: 4
- 文章访问数: 3172
- HTML全文浏览量: 148